Dare Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dare Bioscience, Inc. on April 19, 2021, reporting events that occurred on April 16, 2021. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol "DARE".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
The Board of Directors increased its size from seven to eight members. Sophia N. Ononye-Onyia, Ph.D., M.P.H., M.B.A., was elected as a new Class I independent director. Her term will expire at the 2021 annual meeting of stockholders.
Compensation and Governance Details
- Stock Option Grant: Dr. Ononye-Onyia was granted an option to purchase 45,000 shares of common stock on April 16, 2021.
- Exercise Price: Set at the closing price of the stock on the grant date.
- Vesting Schedule: The option vests in three equal tranches (one-third) on each anniversary of the grant date, contingent on continued service.
- Committee Assignments: No Board committee appointments were made at the time of this filing.
- Indemnification: A standard director indemnification agreement was executed.
Investor Verification Checklist
- Verify the closing stock price on April 16, 2021, to determine the exercise price of the 45,000 share option grant.
- Review the non-employee director compensation policy referenced in the 2020 Form 10-K (Exhibit 10.6) for full details on cash and equity compensation.
- Confirm the date of the 2021 annual meeting of stockholders to determine the expiration of Dr. Ononye-Onyia's director term.
- Monitor future filings for any committee assignments or additional compensation arrangements for the new director.